A new classification for hepatocellular carcinoma with portal vein tumor thrombus

Shi, Jie; Lai, Eric C. H.; Li, Nan; Guo, Wei-Xing; Xue, Jie; Lau, W. Y.; Wu, Mengchao; Cheng, Shuqun

doi:10.1007/s00534-010-0314-0

Cited by 167 publications

(150 citation statements)

References 12 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…these data, miR-155 appears to be involved in tumor progression through the inhibition of multiple tumor suppressor genes, such as sex-determining region Y-gene related high-mobility-group box gene (24,25) and suppressor in cytokine signaling 1 (26), thus promoting proliferation and invasion in HCC. Surgical resection is the typical initial treatment for primary liver cancer (27). This previous demonstrated that the rate of HCC surgery recurrence rate was significantly increased within 1 year of surgery and was accompanied by poor prognosis, compared with the recurrence rate in subsequent years.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of microRNA-155 expression in hepatocellular carcinoma

Guan¹,

Yang²,

He³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate the expression of microRNA-155 (miR-155) in hepatocellular carcinoma (HCC) and adjacent normal tissues, and assess its correlation with clinicopathological characteristics of this tumor type. miR-155 expression was detected in 40 HCC tissue samples and 40 samples of adjacent tumor-free tissue using fluorescent reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The association between miR-155 expression, clinicopathological features and 1-year relapse-free survival (RFS) in HCC and adjacent normal tissue samples was analyzed. RT-qPCR results revealed that, in 25 cases (62.5%), miR-155 expression levels were significantly increased in HCC tissues compared with the expression levels observed in pericarcinomatous tissues (P<0.05). miR-155 expression was observed to be significantly correlated with vessel invasion, Edmonson classification and clinical stage (P<0.05). However, miR-155 expression was not significantly correlated with gender, age, tumor size, tumor number, hepatitis B virus DNA copy number, cirrhosis or concentration of α-fetoprotein (P>0.05). A positive correlation was observed between late TNM classification of malignant tumor stage and 1-year RFS (P<0.05). Patients exhibiting high miR-155 expression levels were observed to exhibit a lower 1-year RFS than that of patients with reduced expression of miR-155 (48 vs. 73.3%), however this difference was not statistically significant (P= 0.105). Additionally, correlations were observed between miR-155 expression and reduced differentiation, increased invasiveness and late stages of HCC. The current results demonstrated that miR-155 may be involved in the tumorigenesis of HCC and may be associated with clinical characteristics of HCC patients. Additional studies are required to clarify the mechanism of miR-155.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical significance of microRNA-155 expression in hepatocellular carcinoma

Guan¹,

Yang²,

He³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Patients with Child-Pugh class C liver function were not considered for resection. 22 Based on the location and extent, PVTT was classified into 4 types according to the study by Shi et al 25 Original Article Type I: tumor thrombi involving the segmental branches of the portal vein or above; type II: tumor thrombi extending to involve the right/left portal vein; type III: the main portal vein; type IV: the superior mesenteric vein. The presence of PVTT was confirmed histopathologically in the resected specimens in the HR group.…”

Section: Patientsmentioning

confidence: 99%

Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus

Peng

Guo

Zhang

et al. 2012

Cancer

144

163

View full text Add to dashboard Cite

BACKGROUND:The long‐term survival outcomes of hepatic resection (HR) compared with transcatheter arterial chemoembolization (TACE) for resectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) are unclear.MATERIALS AND METHODS:Between December 2002 and December 2007, 201 consecutive patients diagnosed with resectable HCC with PVTT received HR as an initial treatment in our center. These patients were compared with 402 case‐matched controls selected from a pool of 1798 patients (with a 1:2 ratio) who received TACE as an initial treatment during the study period. PVTT was classified to 4 types: PVTT involving the segmental branches of the portal vein or above (type I), PVTT extending to involve the right/left portal vein (type II), the main portal vein (type III), or the superior mesenteric vein (type IV).RESULTS:The 1‐, 3‐, and 5‐year overall survivals for the HR and TACE groups were 42.0%, 14.1%, and 11.1% and 37.8%, 7.3%, and 0.5%, respectively (P < .001). On subgroup analyses, the overall survivals for the HR group were better than the TACE group for type I PVTT, type II PVTT, single tumor, and tumor size >5 cm (P < .001, P = .002, P < .001, P < .001, respectively), but not for type III PVTT, type IV PVTT, multiple tumors, and tumor size <5 cm (P = .541, P = .371, P = .264, P = .338, P = .125, respectively). Multivariate analysis showed the type of PVTT and initial treatment allocation were significant prognostic factors for overall survival.CONCLUSIONS:Compared with TACE, HR provided survival benefits for patients with resectable HCC with PVTT, especially for those with a type I PVTT or a type II PVTT. Cancer 2012. © 2012 American Cancer Society.

show abstract

“…In 2007, Shi et al (11) proposed a PVTT classification which was based on the extent of the tumor thrombus in the portal vein, as follows: Type I0, tumor thrombus formation found under microscopy; type I, tumor thrombi involving segmental branches of portal vein or above; type II, tumor thrombi involving right/left portal vein; type III, tumor thrombi involving the main portal vein trunk; and type IV, tumor APTT, activated partial thromboplastin time; HBs, hepatitis B surface; HCV, hepatitis C virus; AFP, α-fetoprotein; CEA, carcinoembryonic antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γGTP, γ-glutamyl transpeptidase; LDH, lactate dehydrogenase; Na, sodium; K, potassium; Cl, chlorine; BUN, blood urea nitrogen; Cr, creatinine.…”

Section: Discussionmentioning

confidence: 99%

Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report

2015

View full text Add to dashboard Cite

Abstract. Portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) is a common entity. However, the prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is extremely poor. The current study reports a case of HCC with PVTT, including a description of the gross surgical pathology and discussion of the relevance of assessing the growth of the tumor thrombus to the outcome of this disease. This case suggests that destruction of the primary tumor and PVTT must be considered according to the growth characteristics and modality of PVTT. It also indicates that transcatheter arterial embolization may be a suitable strategy for palliative treatment of patients with advanced HCC with PVTT.

show abstract

A new classification for hepatocellular carcinoma with portal vein tumor thrombus

Cited by 167 publications

References 12 publications

Clinical significance of microRNA-155 expression in hepatocellular carcinoma

Clinical significance of microRNA-155 expression in hepatocellular carcinoma

Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus

Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report

Contact Info

Product

Resources

About